Human Mesenchymal Stem Cells Reprogram Adult Cardiomyocytes Toward a Progenitor-Like State Through Partial Cell Fusion and Mitochondria Transfer

Abstract

Because stem cells are often found to improve repair tissue including heart without evidence of engraftment or differentiation, mechanisms underlying wound healing are still elusive. Several studies have reported that stem cells can fuse with cardiomyocytes either by permanent or partial cell fusion processes. However, the respective physiological impact of these two processes remains unknown in part because of the lack of knowledge of the resulting hybrid cells. To further characterize cell fusion, we cocultured mouse fully differentiated cardiomyocytes with human multipotent adipose-derived stem (hMADS) cells as a model of adult stem cells. We found that heterologous cell fusion promoted cardiomyocyte reprogramming back to a progenitor-like state. The resulting hybrid cells expressed early cardiac commitment and proliferation markers such as GATA-4, myocyte enhancer factor 2C, Nkx2.5, and Ki67 and exhibited a mouse genotype. Interestingly, human bone marrow-derived stem cells shared similar reprogramming properties than hMADS cells but not human fibroblasts, which suggests that these features might be common to multipotent cells. Furthermore, cardiac hybrid cells were preferentially generated by partial rather than permanent cell fusion and that intercellular structures composed of f-actin and microtubule filaments were involved in the process. Finally, we showed that stem cell mitochondria were transferred into cardiomyocytes, persisted in hybrids and were required for somatic cell reprogramming. In conclusion, by providing new insights into previously reported cell fusion processes, our data might contribute to a better understanding of stem cell-mediated regenerative mechanisms and thus, the development of more efficient stem cell-based heart therapies. STEM CELLS 2011; 29:812-824 Disclosure of potential conflicts of interest is found at the end of this article.

mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation

“…Although these data highlight the importance of MSC secretome in mediating its therapeutic effects, the potential role of other mechanisms, such as exosomes and mitochondrial transfer, should be further evaluated. 50,51 The promising therapeutic potential of MSCs is not yet fully translated into the clinic. Given the narrow window of opportunity to achieve their therapeutic effects, strategies enabling rapid delivery of "upgraded" MSCs to disease sites appear necessary.…”

Mitochondrial DNA in Tumor Initiation, Progression, and Metastasis: Role of Horizontal mtDNA Transfer

“…However, this view was challenged a decade ago when it was shown that membrane connections or cytoplasmic bridges form between cells in culture and that cellular organelles traverse these nanotube connections (1). Since then, considerable in vitro evidence has confirmed organelle transfer, including mitochondria, to and between tumor cells (2)(3)(4)(5)(6)(7)(8) as well as between nontumor cells (9)(10)(11)(12)(13)(14)(15). Additionally, recent phylogenetic evidence suggests that mtDNA can "move" between normal cells and tumor cells in canine venereal transmissible cancer (16,17), while pathophysiological models of lung injury (18,19), lung inflammation (19), and tumor formation by respiration-deficient tumor cells (19) have added weight to intercellular mitochondrial transfer being a new (patho) physiological phenomenon.…”

Somatic cell reprogrammed by oocyte: process and barricade

“…In fact, different types of stem cells only have the capacity to reprogram somatic cells to a certain state, which is identical to the differentiated state of this type of stem cells. As discussed above, after cell fusion, ESCs can reprogram somatic cells to pluripotent cells (Cowan et al 2005), and Yamanaka factors identified from ESCs also have the capacity to reprogram fully differentiated somatic cells to iPSCs (Takahashi & Yamanaka 2006), while human multipotent mesenchymal stem cells only have the capacity to reprogram mouse fully differentiated cardiomyocytes to a progenitor-like state (Acquistapace et al 2011), mouse totipotent zygotes could support the full-term development of mouse ESCs (Egli et al 2007). Therefore, from these points of view, the mechanism of SCNT would be different from that of stem cell-somatic cell fusion and iPSCs.…”